Zilebesiran

Zilebesiran (API)

Research Application:
Zilebesiran API is an investigational small interfering RNA (siRNA) developed for the treatment of hypertension. It targets the AGT gene, which encodes angiotensinogen—a key component of the renin-angiotensin-aldosterone system (RAAS). In research, Zilebesiran is used to study gene silencing approaches for long-term blood pressure control, RNAi delivery technologies, and the broader role of the RAAS pathway in cardiovascular and renal diseases.

Function:
Zilebesiran functions by silencing AGT mRNA in the liver, resulting in reduced production of angiotensinogen. This leads to a downstream decrease in angiotensin II levels, helping to lower blood pressure in a sustained manner. As an API, Zilebesiran enables the development of long-acting, subcutaneous antihypertensive therapies with the potential for quarterly or biannual dosing, offering improved adherence and blood pressure management.